Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 24

1.

Role of Pregabalin in Treatment of Polyneuropathy in Multiple Myeloma Patients: A Retrospective Study.

Maschio M, Mengarelli A, Zarabla A, Giannarelli D, Maialetti A, Gumenyuk S, Renzi D, Palombi F, Pisani F, Romano A, Spadea A, Galiè E, Marchesi F.

Clin Neuropharmacol. 2019 Jul 29. doi: 10.1097/WNF.0000000000000360. [Epub ahead of print]

PMID:
31361668
2.

Vastus lateralis myofascial free flap for tongue reconstruction and hypoglossal-femoral anastomosis: neurophysiological study.

Galiè E, Villani V, Ferreli F, Pace A, Pellini R.

Neurol Sci. 2019 Mar;40(3):553-559. doi: 10.1007/s10072-018-3687-5. Epub 2019 Jan 2.

PMID:
30604334
3.

Prevention of Bortezomib-Related Peripheral Neuropathy With Docosahexaenoic Acid and α-Lipoic Acid in Patients With Multiple Myeloma: Preliminary Data.

Maschio M, Zarabla A, Maialetti A, Marchesi F, Giannarelli D, Gumenyuk S, Pisani F, Renzi D, Galiè E, Mengarelli A.

Integr Cancer Ther. 2018 Dec;17(4):1115-1124. doi: 10.1177/1534735418803758. Epub 2018 Oct 8.

4.

Tapentadol in neuropathic pain cancer patients: a prospective open label study.

Galiè E, Villani V, Terrenato I, Pace A.

Neurol Sci. 2017 Oct;38(10):1747-1752. doi: 10.1007/s10072-017-3035-1. Epub 2017 Jul 11.

PMID:
28699105
5.

Paraneoplastic Morvan's syndrome following surgical treatment of recurrent thymoma: A case report.

Galié E, Renna R, Plantone D, Pace A, Marino M, Jandolo B, Koudriavtseva T.

Oncol Lett. 2016 Oct;12(4):2716-2719. Epub 2016 Jul 29.

6.

Multiple sclerosis activated by anti-tumor necrosis factor α (Etanercept) and the genetic risk.

Galiè E, Jandolo B, Martayane A, Renna R, Koudriavtseva T.

Neurol India. 2016 Sep-Oct;64(5):1042-4. doi: 10.4103/0028-3886.190240. No abstract available.

7.

Vitamin E neuroprotection against cisplatin ototoxicity: Preliminary results from a randomized, placebo-controlled trial.

Villani V, Zucchella C, Cristalli G, Galiè E, Bianco F, Giannarelli D, Carpano S, Spriano G, Pace A.

Head Neck. 2016 Apr;38 Suppl 1:E2118-21. doi: 10.1002/hed.24396. Epub 2016 Feb 5.

PMID:
26849799
8.

Correspondence between neurophysiological and clinical measurements of chemotherapy-induced peripheral neuropathy: secondary analysis of data from the CI-PeriNomS study.

Griffith KA, Dorsey SG, Renn CL, Zhu S, Johantgen ME, Cornblath DR, Argyriou AA, Cavaletti G, Merkies IS, Alberti P, Postma TJ, Rossi E, Frigeni B, Bruna J, Velasco R, Kalofonos HP, Psimaras D, Ricard D, Pace A, Galie E, Briani C, Dalla Torre C, Faber CG, Lalisang RI, Boogerd W, Brandsma D, Koeppen S, Hense J, Storey DJ, Kerrigan S, Schenone A, Fabbri S, Valsecchi MG; CI-PeriNomS Group.

J Peripher Nerv Syst. 2014 Jun;19(2):127-35. doi: 10.1111/jns5.12064.

9.

Physician-assessed and patient-reported outcome measures in chemotherapy-induced sensory peripheral neurotoxicity: two sides of the same coin.

Alberti P, Rossi E, Cornblath DR, Merkies IS, Postma TJ, Frigeni B, Bruna J, Velasco R, Argyriou AA, Kalofonos HP, Psimaras D, Ricard D, Pace A, Galiè E, Briani C, Dalla Torre C, Faber CG, Lalisang RI, Boogerd W, Brandsma D, Koeppen S, Hense J, Storey D, Kerrigan S, Schenone A, Fabbri S, Valsecchi MG, Cavaletti G; CI-PeriNomS Group.

Ann Oncol. 2014 Jan;25(1):257-64. doi: 10.1093/annonc/mdt409. Epub 2013 Nov 19.

10.

Rasch-built Overall Disability Scale for patients with chemotherapy-induced peripheral neuropathy (CIPN-R-ODS).

Binda D, Vanhoutte EK, Cavaletti G, Cornblath DR, Postma TJ, Frigeni B, Alberti P, Bruna J, Velasco R, Argyriou AA, Kalofonos HP, Psimaras D, Ricard D, Pace A, Galiè E, Briani C, Dalla Torre C, Lalisang RI, Boogerd W, Brandsma D, Koeppen S, Hense J, Storey D, Kerrigan S, Schenone A, Fabbri S, Rossi E, Valsecchi MG, Faber CG, Merkies IS; CI-PeriNomS study group, Galimberti S, Lanzani F, Mattavelli L, Piatti ML, Bidoli P, Cazzaniga M, Cortinovis D, Lucchetta M, Campagnolo M, Bakkers M, Brouwer B, Boogerd W, Grant R, Reni L, Piras B, Pessino A, Padua L, Granata G, Leandri M, Ghignotti I, Plasmati R, Pastorelli F, Heimans JJ, Eurelings M, Meijer RJ, Grisold W, Lindeck Pozza E, Mazzeo A, Toscano A, Russo M, Tomasello C, Altavilla G, Penas Prado M, Dominguez Gonzalez C, Dorsey SG.

Eur J Cancer. 2013 Sep;49(13):2910-8. doi: 10.1016/j.ejca.2013.04.004. Epub 2013 May 10.

PMID:
23668917
11.

A possible case of Hashimoto's encephalopathy after surgery and radiometabolic therapy for thyroid carcinoma.

Onesti E, Koudriavtseva T, Galiè E, Anelli V, Jandolo B.

Neurol Sci. 2013 Aug;34(8):1489-91. doi: 10.1007/s10072-012-1234-3. Epub 2012 Nov 17. No abstract available.

PMID:
23161258
12.

The chemotherapy-induced peripheral neuropathy outcome measures standardization study: from consensus to the first validity and reliability findings.

Cavaletti G, Cornblath DR, Merkies IS, Postma TJ, Rossi E, Frigeni B, Alberti P, Bruna J, Velasco R, Argyriou AA, Kalofonos HP, Psimaras D, Ricard D, Pace A, Galiè E, Briani C, Dalla Torre C, Faber CG, Lalisang RI, Boogerd W, Brandsma D, Koeppen S, Hense J, Storey D, Kerrigan S, Schenone A, Fabbri S, Valsecchi MG; CI-PeriNomS Group.

Ann Oncol. 2013 Feb;24(2):454-62. doi: 10.1093/annonc/mds329. Epub 2012 Aug 21.

13.

Neuroprotective strategies in the prevention of chemotherapy-induced neuropathies.

Pace A, Galiè E, Koudriavtseva T.

Support Care Cancer. 2013 Jan;21(1):1-2. doi: 10.1007/s00520-012-1552-2. Epub 2012 Aug 4. No abstract available.

PMID:
22864471
14.

Vitamin E neuroprotection for cisplatin neuropathy: a randomized, placebo-controlled trial.

Pace A, Giannarelli D, Galiè E, Savarese A, Carpano S, Della Giulia M, Pozzi A, Silvani A, Gaviani P, Scaioli V, Jandolo B, Bove L, Cognetti F.

Neurology. 2010 Mar 2;74(9):762-6. doi: 10.1212/WNL.0b013e3181d5279e.

PMID:
20194916
15.

Bilateral whirlbone necrosis in a young multiple sclerosis patient.

Galiè E, Jandolo B.

Neurol Sci. 2010 Apr;31(2):197-8. doi: 10.1007/s10072-009-0177-9.

PMID:
20066553
16.

Peripheral neurotoxicity of weekly paclitaxel chemotherapy: a schedule or a dose issue?

Pace A, Nisticò C, Cuppone F, Bria E, Galiè E, Graziano G, Natoli G, Sperduti I, Jandolo B, Calabretta F, Tomao S, Terzoli E.

Clin Breast Cancer. 2007 Apr;7(7):550-4.

PMID:
17509163
17.

Luminance and chromatic visual evoked potentials in type I and type II diabetes: relationships with peripheral neuropathy.

Gregori B, Galié E, Pro S, Clementi A, Accornero N.

Neurol Sci. 2006 Nov;27(5):323-7.

PMID:
17122941
18.

Cerebellar atrophy and monoclonal gammopathy of undetermined significance: a possible correlation?

Galiè E, Maschio M, Jandolo B.

J Exp Clin Cancer Res. 2005 Sep;24(3):483-5.

PMID:
16270536
19.

Surface electromyography and mechanomyography recording: a new differential composite probe.

Gregori B, Galié E, Accornero N.

Med Biol Eng Comput. 2003 Nov;41(6):665-9.

PMID:
14686592
20.

Temozolomide chemotherapy for progressive low-grade glioma: clinical benefits and radiological response.

Pace A, Vidiri A, Galiè E, Carosi M, Telera S, Cianciulli AM, Canalini P, Giannarelli D, Jandolo B, Carapella CM.

Ann Oncol. 2003 Dec;14(12):1722-6.

PMID:
14630675
21.

Demyelinating disease in monoclonal gammopathy of undetermined significance.

Galiè E, Pietrangeli A, Maschio M, Pace A, Vidiri A, Carosi M, Jandolo B.

J Exp Clin Cancer Res. 2003 Jun;22(2):337-9.

PMID:
12866587
22.

Masseteric silent period and reflex before and after dentomaxillofacial surgery.

Jandolo B, Galiè E, Badia D.

Neurol Sci. 2003 Jun;24(2):53-6.

PMID:
12827538
23.

A new color vep procedure discloses asymptomatic visual impairments in optic neuritis and glaucoma suspects.

Accornero N, Gregori B, Galié E, De Feo A, Agnesi R.

Acta Neurol Scand. 2000 Oct;102(4):258-63.

PMID:
11071112

Supplemental Content

Support Center